Biologická léčba bronchiálního astmatu: současný stav a výhled do budoucna
| Title in English | Biological treatment of bronchial asthma: current status and future prospects |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Article in Periodical |
| Magazine / Source | Studia pneumologica et phthiseologica |
| MU Faculty or unit | |
| Citation | |
| Web | http://www.pneumologie.cz/cislo/1924/4-2021/?potvrzeni1=1&potvrzeni2=1&potvrdit=ANO%0D%0A%0D%0A++++Vstoupit# |
| Keywords | asthma; bronchial asthma; biological therapy; omalizumab; mepolizumab; reslizumab; benralizumab; dupilumab |
| Description | Biological therapies have revolutionised the treatment of many severe asthma patients who are unable to get their disease under control. Although a relatively small proportion of asthmatics, these patients have high morbidity rates and a lower quality of life despite all available treatments. Understanding the pathogenesis of asthma has made it possible to target their therapy directly and to influence the different inflammatory pathways involved in the onset and development of asthma. In particular, patients with the "type-2 high" phenotype of inflammation, in whom biological therapy significantly reduced the number of exacerbations, improved lung function and allowed a reduction in the doses of oral corticosteroids used. We now have the ability to administer anti-IgE antibodies (omalizumab) to help patients with allergic asthma, as well as antibodies that interfere with interleukin 5 signaling pathways (mepolizumab, reslizumab, benralizumab) and interleukin 4 with interleukin 13 (dupilumab). Despite recent advances in the treatment of patients with severe asthma, there remains a continuing need for the development of additional biologics, particularly for patients with the 'type-2 low' asthma phenotype, and there is also a continuing lack of comparison of available biologics with each other. |
| Related projects: |